Goodwin Biotech, Rafagen In Cell Line Pact
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Goodwin Biotechnology, Inc. (GBI) and Rafagen, Inc. have entered a collaboration agreement for cell line engineering and biological contract manufacturing. Terms of the agreement were not disclosed.
"We seek to address unmet needs of patients with inherited and acquired diseases," said Sung Ho Hahm, Ph.D., co-founder, president and chief executive officer of Rafagen.
Hahm continued, "With Rafagen's proprietary technology platforms, the highest producing cell lines will be established at a fraction of the time currently required. This translates the promise of science into tangible therapies that restore health and save lives."
"By collaborating with Rafagen for cell line engineering, we at GBI can expand our capabilities as a biological contract manufacturing organization and offer one-stop shopping," noted SooYoung Lee, Ph.D., senior vice president at GBI.
Lee continued, "This enables our clients to overcome challenging projects by working from their cDNA to develop more robust and high productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes."
"We seek to address unmet needs of patients with inherited and acquired diseases," said Sung Ho Hahm, Ph.D., co-founder, president and chief executive officer of Rafagen.
Hahm continued, "With Rafagen's proprietary technology platforms, the highest producing cell lines will be established at a fraction of the time currently required. This translates the promise of science into tangible therapies that restore health and save lives."
"By collaborating with Rafagen for cell line engineering, we at GBI can expand our capabilities as a biological contract manufacturing organization and offer one-stop shopping," noted SooYoung Lee, Ph.D., senior vice president at GBI.
Lee continued, "This enables our clients to overcome challenging projects by working from their cDNA to develop more robust and high productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes."
